RN1006 has been developed as a stabilized formulation of avotermin which, when dosed once in pre-clinical studies in animals, has shown comparable scar improvement efficacy to the standard twice-dosed Juvista formulation. The aim of this trial is to investigate the efficacy of RN1006 compared to Juvista in a human volunteer model
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
84
250 ng, twice, intradermal injection, standard formulation
250 ng, intradermal injection, twice
205 ng, Intradermal injection, once
Renovo CTU
Manchester, United Kingdom
Global scar comparison scale
Time frame: 12 months
Adverse event incidence including specific assessment of local tolerability at the treated wound site
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
500ng, intradermal injection, once
250 ng, intradermal injection, twice
500 ng, intradermal injection, once
500 ng, intradermal injection, once
500 ng, intradermal injection, twice
Placebo